This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lassam, N. J. Articles by Kahn, H. J. Search for Related Content PubMed PubMed Citation Articles by Lassam, N. J. Articles by Kahn, H. J.

Overexpression of p53 Is a Late Event in the Development of Malignant Melanoma¹

Departments of Medicine [N. J. L.] and Pathology [L. F., H. J. K.], University of Toronto, Toronto, Ontario, Canada; Toronto-Bayview Regional Cancer Center, Toronto, Ontario, Canada M4N 3M5 [N. J. L.]; and Woman's College Hospital, Toronto, Ontario, Canada M5S 1B2 [L. F., H. J. K.]

Overexpression of the p53 gene product has been observed in a high percentage of malignant melanomas. To evaluate the role of this protein in the development of melanoma, we examined p53 expression in benign, premalignant, and malignant melanocytic lesions. Using the antibodies DO-7 and 1801, which recognize both wild-type and most mutant forms of the p53 protein, we analyzed by immunohistochemical staining 26 benign nevi, 34 dysplastic nevi from patients at low risk for the development of melanoma, 22 dysplastic nevl from patients at high risk for the development of melanoma, 61 primary melanomas (including 15 that arose from dysplastic nevi), and 10 metastatic melanomas. Expression of the p53 protein was not observed in any of the benign or dysplastic nevi. Of the primary melanomas only 3 (5%) demonstrated nuclear staining, whereas 70% of the metastatic melanomas showed a positive reaction for p53. These data suggest that overexpression of the p53 gene product is a late event in the progression of melanoma and consequently indicate that expression of this protein cannot be used as a marker to identify patients at high risk for the subsequent development of melanoma.

¹ This work was supported in part by the Medical Research Council of Canada. N. J. L. is a Cancer Research Society/Medical Research Council Scholar.

² To whom requests for reprints should be addressed, at Toronto-Bayview Regional Cancer Center, 2075 Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5.

Received 3/22/93. Accepted 4/ 2/93.

This article has been cited by other articles:

				L. Le Marchand, B. S. Saltzman, J. H. Hankin, L. R. Wilkens, A. A. Franke, S. J. Morris, and L. N. Kolonel Sun Exposure, Diet, and Melanoma in Hawaii Caucasians Am. J. Epidemiol., August 1, 2006; 164(3): 232 - 245. [Abstract] [Full Text] [PDF]

				C. J. Cohen, Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR J. Immunol., November 1, 2005; 175(9): 5799 - 5808. [Abstract] [Full Text] [PDF]

				M R Hussein Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues J. Clin. Pathol., May 1, 2005; 58(5): 453 - 456. [Abstract] [Full Text] [PDF]

				A. Koenig, S. R. Bianco, S. Fosmire, J. Wojcieszyn, and J. F. Modiano Expression and Significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN Tumor Suppressors in Canine Melanoma Vet. Pathol., July 1, 2002; 39(4): 458 - 472. [Abstract] [Full Text] [PDF]

				M. R. A.-E. Hussein and G. S. Wood Molecular Aspects of Melanocytic Dysplastic Nevi J. Mol. Diagn., May 1, 2002; 4(2): 71 - 80. [Abstract] [Full Text] [PDF]

				K. Satyamoorthy, N. H. Chehab, M. J. F. Waterman, M. C. Lien, W. S. El-Deiry, M. Herlyn, and T. D. Halazonetis Aberrant Regulation and Function of Wild-Type p53 in Radioresistant Melanoma Cells Cell Growth Differ., September 1, 2000; 11(9): 467 - 474. [Abstract] [Full Text]

				T. Haapajärvi, K. Pitkänen, and M. Laiho Human Melanoma Cell Line UV Responses Show Independency of p53 Function Cell Growth Differ., March 1, 1999; 10(3): 163 - 171. [Abstract] [Full Text]

				J S Chana, G D Wilson, I A Cree, R A Alexander, N Myatt, M Neale, A J E Foss, and J L Hungerford c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma Br. J. Ophthalmol., January 1, 1999; 83(1): 110 - 114. [Abstract] [Full Text]

				Z. Kaleem, A. C. Lind, P. A. Humphrey, P. E. Swanson, R. H. Sueper, J. H. Ritter, and M. R. Wick Immunohistologic Evaluation of Putatively Mutant p53 Protein in Cutaneous Melanocytic Neoplasms: A Study of 256 Cases International Journal of Surgical Pathology, April 1, 1998; 6(2): 73 - 79. [Abstract] [PDF]

				S. Gnjatic, Z. Cai, M. Viguier, S. Chouaib, J.-G. Guillet, and J. Choppin Accumulation of the p53 Protein Allows Recognition by Human CTL of a Wild-Type p53 Epitope Presented by Breast Carcinomas and Melanomas J. Immunol., January 1, 1998; 160(1): 328 - 333. [Abstract] [Full Text] [PDF]